Standigm utilizes artificial intelligence to enhance drug discovery through first-in-class target identification and lead optimization, significantly reducing the average material optimization time from 4.5 years to 1.5 years. The platform provides end-to-end solutions that improve the efficiency and success rates of new drug development processes.
Funding
$71.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PCFounders
Product
Problem
The drug discovery process is often lengthy and inefficient, with material optimization taking an average of 4.5 years. Traditional methods struggle to quickly identify promising drug targets and optimize lead compounds for desired properties.
Solution
Standigm offers AI-driven SaaS and API solutions to accelerate and enhance drug discovery, specifically in target identification and lead optimization. The platform leverages artificial intelligence and knowledge graphs to identify first-in-class targets and optimize lead compounds, significantly reducing the material optimization timeline to approximately 1.5 years. By providing end-to-end AI solutions, Standigm improves the efficiency and success rates of new drug development.
Target Audience
The primary audience includes pharmaceutical companies and research institutions seeking to improve the efficiency and success rates of their drug discovery programs.
Features
- AI-powered target identification to discover novel drug targets.
- Lead optimization algorithms to enhance drug candidates for diverse properties.
- AI SaaS and API solutions for seamless integration into existing workflows.
- Knowledge graph integration for comprehensive data analysis and insights.